I think it is pretty obvious that AEZS sees their main hope for the future as 108, and the ERK inhibitors to follow. Peri has always simply been an end to a means for them, and will hopefully, in another year or so eliminate the need for any further ATMs.
This barely qualifies as news. Its preclinical stuff. I literally did an MTT assay yesterday and am finishing up a PARP cleavage immunoblot today for a biotech partnered with my lab (Not AEZS).
This is still ways down the road. Possibly another year til even phase 1. Not sure how they are doing in the in vivo studies.
Yes, its good for the pipeline, but it should not warrant a 1/10th of a cent increase until it shows phase 1 efficacy.
And thats from a long! Just being honest folks.
Drfil, I wouldn't say it hardly qualifies as news. It is after all another compound in the pipeline. I agree that this is years (and millions of dollars) away from being a viable breast cancer drug, but still, look at drug development. How many thousands of compounds are tested and rejected before they even come close to pre-clinical stage? The fact that the company is possibly advancing this towards pre-clinical is a significant step. Yes, the odds are still great that this compound may not amount to anything,but this company has demonstrated that it is in the forefront of developing ERK inhibitors, which will eventually become very useful drugs in the oncologists' armamentarium. It is also the type of expertise that piques the interest of big pharma.
Would you please stop the yelling (all caps) and the multiple exclamation points.
This is a nice little pre-clinical study. Incrementally it shows that AEZS has a good pipeline.
But "wow jackpot"? Maybe in 5 years....
This board does not benefit from such a post.
Are you stupid or are you pumping?
It is certainly good news to support the depth of AEZS' pipeline. At such a low share price with such formidable potential in its pipeline, large pharmas needing new drugs will be interested in looking further into this co. There are some validity in the rumor concerning buy-out, although at this stage, shareholders may not get the fair share price based on the premium added to the current price. I'd rather wait for it to take place next year when we'll have a couple approved drugs under our belt.